商業快報

Psychedelic nasal spray shows promise against depression

Mebufotenin benzoate also required a much shorter period of clinical supervision in trial

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against treatment-resistant depression, giving biotechs hope that this type of drug will become a viable option for healthcare systems to use for mental health conditions. 

Atai Life Sciences and Beckley Psytech announced on Tuesday that patients in their trial of mebufotenin benzoate — based on a compound found in many plants and the venom of the Colorado River toad — demonstrated “clinically meaningful” reductions in depressive symptoms that started as soon as the day after treatment.

The effect of a single treatment lasted for the trial of eight weeks without plateauing by the end and there were no serious side effects.

您已閱讀22%(728字),剩餘78%(2639字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×